<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0002863'>Myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) are a group of common <z:e sem="disease" ids="C0005956" disease_type="Disease or Syndrome" abbrv="">bone marrow disorders</z:e> characterized by ineffective hematopoiesis, peripheral cytopenias, and a propensity for transformation to <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>For many years, the main treatment option for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> was best supportive care which alleviates symptoms but has no effect on the natural course of the disease </plain></SENT>
<SENT sid="2" pm="."><plain>The recent approval of the demethylating agent <z:chebi fb="0" ids="2038">azacitidine</z:chebi> represents a significant advance in the treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>The results of two randomized trials with <z:chebi fb="0" ids="2038">azacitidine</z:chebi> have shown an overall response rate between 40% and 60%, an improved quality of life, a reduced risk of transformation to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and a definite survival advantage compared to best supportive care or low-dose chemotherapy </plain></SENT>
<SENT sid="4" pm="."><plain>Current data on <z:chebi fb="0" ids="2038">azacitidine</z:chebi> and its place in the treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> are reviewed </plain></SENT>
</text></document>